These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 14710346

  • 1. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells.
    Strammiello R, Benini S, Manara MC, Perdichizzi S, Serra M, Spisni E, Picci P, Scotlandi K.
    Horm Metab Res; 2003; 35(11-12):675-84. PubMed ID: 14710346
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S, Manara MC, Baldini N, Cerisano V, Massimo Serra, Mercuri M, Lollini PL, Nanni P, Picci P, Scotlandi K.
    Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
    [Abstract] [Full Text] [Related]

  • 3. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
    Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, Johnston C, Laurence V, Burchill SA.
    Clin Cancer Res; 2005 Mar 15; 11(6):2364-78. PubMed ID: 15788688
    [Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
    Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, Picci P, Manara MC, Baldini N.
    Cancer Res; 1996 Oct 15; 56(20):4570-4. PubMed ID: 8840962
    [Abstract] [Full Text] [Related]

  • 5. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y, Wang S, Hoot DR, Clinton SK.
    J Nutr Biochem; 2007 Jun 15; 18(6):408-17. PubMed ID: 17142033
    [Abstract] [Full Text] [Related]

  • 6. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration.
    Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K, Chou AJ, Koshkina NV, Kleinerman ES.
    Cancer; 2007 Oct 01; 110(7):1568-77. PubMed ID: 17694551
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.
    Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, Armatis P.
    Cancer; 2002 Oct 15; 95(8):1735-45. PubMed ID: 12365022
    [Abstract] [Full Text] [Related]

  • 8. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
    Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES.
    Clin Cancer Res; 2005 Apr 01; 11(7):2662-9. PubMed ID: 15814647
    [Abstract] [Full Text] [Related]

  • 9. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo.
    Zhou Z, Reddy K, Guan H, Kleinerman ES.
    Mol Cancer Res; 2007 Nov 01; 5(11):1125-32. PubMed ID: 18025258
    [Abstract] [Full Text] [Related]

  • 10. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, García-Echeverría C, Picci P, Scotlandi K.
    Clin Cancer Res; 2007 Feb 15; 13(4):1322-30. PubMed ID: 17317844
    [Abstract] [Full Text] [Related]

  • 11. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
    Ling MT, Lau TC, Zhou C, Chua CW, Kwok WK, Wang Q, Wang X, Wong YC.
    Carcinogenesis; 2005 Oct 15; 26(10):1668-76. PubMed ID: 15905202
    [Abstract] [Full Text] [Related]

  • 12. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
    Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, Hicklin DJ, Kleinerman ES.
    Clin Cancer Res; 2007 Aug 15; 13(16):4867-73. PubMed ID: 17699866
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
    Girnita L, Wang M, Xie Y, Nilsson G, Dricu A, Wejde J, Larsson O.
    Anticancer Drug Des; 2000 Feb 15; 15(1):67-72. PubMed ID: 10888037
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES.1.
    Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M.
    Oncol Rep; 2005 Feb 15; 13(2):253-7. PubMed ID: 15643507
    [Abstract] [Full Text] [Related]

  • 15. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.
    Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Serra M, Manara MC, Picci P, Baldini N.
    Cancer Res; 1998 Sep 15; 58(18):4127-31. PubMed ID: 9751624
    [Abstract] [Full Text] [Related]

  • 16. Hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in kaposi sarcoma and modulated by insulin-like growth factor-I.
    Catrina SB, Botusan IR, Rantanen A, Catrina AI, Pyakurel P, Savu O, Axelson M, Biberfeld P, Poellinger L, Brismar K.
    Clin Cancer Res; 2006 Aug 01; 12(15):4506-14. PubMed ID: 16899596
    [Abstract] [Full Text] [Related]

  • 17. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
    Benini S, Manara MC, Cerisano V, Perdichizzi S, Strammiello R, Serra M, Picci P, Scotlandi K.
    Int J Cancer; 2004 Jan 20; 108(3):358-66. PubMed ID: 14648701
    [Abstract] [Full Text] [Related]

  • 18. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype.
    Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O.
    Cancer Res; 1999 Aug 01; 59(15):3588-91. PubMed ID: 10446966
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, García-Echeverría C, Hofmann F, Picci P.
    Cancer Res; 2005 May 01; 65(9):3868-76. PubMed ID: 15867386
    [Abstract] [Full Text] [Related]

  • 20. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D.
    Oncogene; 2005 Dec 01; 24(54):8025-37. PubMed ID: 16116481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.